Doxorubicin Hydrochloride Liposome-Based CHOP Regimen in the Initial Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Study.
10.19746/j.cnki.issn.1009-2137.2021.04.018
- Author:
Xiang-Dong WANG
1
;
Bo GUO
2
;
Bing ZHAI
2
;
Bo YANG
2
;
Hui FAN
2
;
Xue-Chun LU
2
;
Su-Xia LI
2
;
Hong-Li ZHU
3
Author Information
1. Graduate School of Chinese PLA General Hospital,Beijing 100853, China,Department of Hematology, The Second Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
2. Department of Hematology, The Second Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
3. Department of Hematology, The Second Medical Center of Chinese PLA General Hospital, Beijing 100853, China,E-mail: bjzhuhl301@vip.sina.com.
- Publication Type:Journal Article
- MeSH:
Aged;
Aged, 80 and over;
Antineoplastic Combined Chemotherapy Protocols;
Cyclophosphamide/therapeutic use*;
Doxorubicin/therapeutic use*;
Humans;
Liposomes/therapeutic use*;
Lymphoma, Large B-Cell, Diffuse/drug therapy*;
Prednisolone;
Prednisone/therapeutic use*;
Retrospective Studies;
Rituximab/therapeutic use*;
Vincristine/therapeutic use*
- From:
Journal of Experimental Hematology
2021;29(4):1136-1140
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the efficacy and safety of CHOP regimen based on doxorubicin hydrochloride liposome in the initial treatment of elderly patients with diffuse large B-cell lymphoma (DLBCL).
METHODS:Thirty-one patients with DLBCL treated from January 1, 2012 to December 31, 2019 were analyzed retrospectively, their median age was 83 (71-95) years old, and all of them were in Ⅲ-Ⅳ stage, including 17 cases who had international prognostic index (IPI) ≥ 3. The patients were treated with R-CHOP and CHOP regimens based on doxorubicin hydrochloride liposome. The efficacy and safety were evaluated during and after treatment.
RESULTS:A total of 219 chemotherapy cycles and 7 median cycles were performed in 31 patients. The overall response (OR) rate and complete remission (CR) rate was 80.7% (25/31) and 61.3% (19/31), respectively, as well as 2 cases (6.5%) stable, 4 cases (12.9%) progressive. The main toxicities were as follows: the incidence of grade Ⅲ -Ⅳ neutropenia was 29% (9/31); two patients (6.5%) developed degree Ⅰ-Ⅱ cardiac events, which were characterized by new degree Ⅰ atrioventricular block; there were no cardiac events requiring emergency treatment and discontinuation of chemotherapy. The 1-year, 2-year and 3-year overall survival rate was 83.9%, 77.4% and 61.3%, respectively. The 1-year, 2-year and 3-year progression-free survival rate was 77.4%, 64.5% and 61.3%, respectively.
CONCLUSION:The chemotherapy regimen based on doxorubicin hydrochloride liposome has better efficacy and higher cardiac safety for elderly patients with DLBCL.
